IWP
ATXI

Icon Wealth Partners’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Icon Wealth Partners’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-533
Closed -$46.6K – 435
2023
Q1 		$46.6K Buy
+533
New +$49.2K 0.01% 417

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Icon Wealth Partners's ATXI Position: Q2 2023 in Review

Icon Wealth Partners sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2023, closing a stake of 533 shares — an estimated $46.6K sold.

Icon Wealth Partners first reported a position in ATXI in Q1 2023 and held it in 1 quarter. The position peaked at $46.6K in Q1 2023. 11 funds tracked by Wall St. Rank hold ATXI as of Q2 2023.

  • Icon Wealth Partners reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Icon Wealth Partners sold 533 Avenue Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $46.6K.
  • Icon Wealth Partners first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Icon Wealth Partners's Avenue Therapeutics, Inc. Common Stock position peaked at $46.6K in Q1 2023.
  • 11 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Icon Wealth Partners's 13F filing for Q2 2023, filed 3 Aug 2023.